
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC is positioned favorably due to its strong clinical activity manifestations, particularly regarding the IMC-F106C and its increasing probability of success in various therapeutic areas, including non-small cell lung cancer (NSCLC). The company's flagship product, KIMMTRAK, has demonstrated a substantial survival advantage over existing treatments for metastatic uveal melanoma, leading to solid early sales and quick market adoption. Moreover, anticipated data readouts related to their pipeline products could serve as significant catalysts, further solidifying Immunocore's leadership in TCR-based immunotherapies and enhancing its positive investment outlook.
Bears say
Immunocore Holdings faces a negative outlook primarily due to the bear case assumptions highlighting potential clinical shortcomings, with minimal expected benefit from its PRAME clinical readouts and low projected probabilities of success for therapies targeting various cancers. Additionally, the company's struggle to develop effective therapies against HIV, particularly given the virus's ability to evade immune responses and the complexities involved in treatment safety and scalability, further dampens its future prospects. The reliance on its ImmTAC, ImmTAV, and ImmTAI platforms for generating successful clinical candidates raises concerns about the company’s overall capacity to innovate and achieve sustained growth in its drug pipeline.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares